Navigation Links
HCA Announces Final Results for its Debt Tender Offer

NASHVILLE, Tenn., March 7 /PRNewswire/ -- HCA Inc. announced today the final results for its debt tender offer to purchase up to $500 million of its debt securities specified in the table below. The tender offer expired at midnight, New York City time, on March 6, 2008. The tender offer was made on the terms and subject to the conditions set forth in the Offer to Purchase dated February 7, 2008 and the related Letter of Transmittal.

The table below identifies the principal amount of each series of securities validly tendered in the tender offer and the principal amount of each series of securities that HCA has accepted for purchase pursuant to the tender offer, as well as the approximate pro-ration factor for each series. The amounts of each series of securities to be purchased in the tender offer were determined based on the aggregate principal amount of each series of securities validly tendered and not validly withdrawn on or before the expiration date, in accordance with the priorities identified in the "Acceptance Priority Level" column in the table below and subject to the maximum tender offer amount of $500 million and the maximum tender cap of $200 million applicable to the 8.750% Notes due 2010.

Based on the aggregate principal amount of securities tendered on or before the expiration date and the terms of the tender offer, HCA will purchase (i) $200,000,000 aggregate principal amount of the 8.750% Notes due 2010 validly tendered and not validly withdrawn, which represents a pro-ration factor of approximately 61.9 percent, (ii) $202,499,000 aggregate principal amount of the 7.875% Notes due 2011 validly tendered and not validly withdrawn, which represents a pro-ration factor of approximately 80.0 percent and (iii) $97,501,000 aggregate principal amount of the 6.950% Notes due 2012 validly tendered and not validly withdrawn, which represents a pro-ration factor of approximately 80.0 percent. The applicable total consideration or tender offer consideration for the securities accepted for purchase, as the case may be, plus accrued and unpaid interest is expected to be paid by HCA on March 11, 2008 in accordance with the terms of the tender offer. Notes that have been tendered but not accepted will be promptly returned to the tendering parties.





Prior to

Settlement of

CUSIP Number Title of Security the Tender Offer Maximum Tender Cap

404119AA7 8.750% Notes due 2010 $691,170,000 $200,000,000

404119AC3 7.875% Notes due 2011 $475,820,000 --

404119AE9 6.950% Notes due 2012 $500,000,000 --


Acceptance Aggregate Principal Approximate

Priority Principal Amount Accepted Pro-ration

Level Amount Tendered for Purchase Factor

1 $322,871,000 $200,000,000 61.9%

2 $253,077,000 $202,499,000 80.0%

2 $121,856,000 $97,501,000 80.0%

Citi served as dealer manager for the tender offer. Global Bondholders Services Corporation served as the information agent and depositary for the tender offer.

The tender offer has been made only by the Offer to Purchase and the related Letter of Transmittal, and the information in this news release is qualified by reference to such documents. Persons with questions regarding the tender offer should contact Citi at (800) 558-3745 (toll-free) or (212) 723- 6106 (collect).

About HCA Inc.

HCA Inc. is the nation's leading provider of healthcare services. As of December 31, 2007, we operated 169 hospitals and 108 freestanding surgery centers in 20 states and England (including eight hospitals and nine freestanding surgery centers operated through equity method joint ventures) and had approximately 186,000 employees. For the year ended December 31, 2007, we generated revenues of $26.858 billion and net income of $874 million.

This press release contains "forward-looking statements" which involve risks and uncertainties. Forward-looking statements include all statements that do not relate solely to historical or current facts, and can be identified by the use of words like "may", "believe", "will", "expect", "intend", "project", "estimate", "anticipate", "plan", "initiative" or "continue." These forward-looking statements are based on our current plans and expectations and are subject to a number of known and unknown uncertainties and risks, many of which are beyond our control, which could significantly affect current plans and expectations and our future financial position and results of operations. These factors include, but are not limited to, (1) the ability to recognize the benefits of the recapitalization of the Company (the "Recapitalization") described in the Company's reports filed with the Securities and Exchange Commission (the "Commission") pursuant to the Securities Exchange Act of 1934, as amended (the "Exchange Act"), (2) the impact of the substantial indebtedness incurred to finance the Recapitalization, (3) increases in the amount and risk of collectibility of uninsured accounts and deductibles and copayment amounts for insured accounts, (4) the ability to achieve operating and financial targets, and attain expected levels of patient volumes and control the costs of providing services, (5) possible changes in the Medicare, Medicaid and other state programs, including Medicaid supplemental payments pursuant to upper payment limit programs, that may impact reimbursements to health care providers and insurers, (6) the highly competitive nature of the health care business, (7) changes in revenue mix and the ability to enter into and renew managed care provider agreements on acceptable terms, (8) the efforts of insurers, health care providers and others to contain health care costs, (9) the outcome of our continuing efforts to monitor, maintain and comply with appropriate laws, regulations, policies and procedures and our Corporate Integrity Agreement with the government, (10) changes in federal, state or local laws or regulations affecting the health care industry, (11) increases in wages and the ability to attract and retain qualified management and personnel, including affiliated physicians, nurses and medical and technical support personnel, (12) the possible enactment of federal or state health care reform, (13) the availability and terms of capital to fund the expansion of our business and improvements to our existing facilities, (14) changes in accounting practices, (15) changes in general economic conditions nationally and regionally in our markets, (16) future divestitures which may result in charges, (17) changes in business strategy or development plans, (18) delays in receiving payments for services provided, (19) the outcome of pending and any future tax audits, appeals and litigation associated with our tax positions, (20) potential liabilities and other claims that may be asserted against us, (21) our ability to complete the tender offer and reduce interest expense and (22) other risk factors described in our Exchange Act reports and other filings with the Commission. As a consequence, current plans, anticipated actions and future financial position and results may differ from those expressed in any forward-looking statements made by or on behalf of the Company. You are cautioned not to unduly rely on such forward-looking statements.

Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
2. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
3. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
4. HEI, Inc. Announces Sale of RFID Division Assets
5. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
6. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
7. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
8. Brooke Franchise Corporation Announces Selected July Results
9. Manor Care, Inc. Announces Record Date for Special Stockholder Meeting
10. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
11. Planet Technologies Announces Agreement to Acquire Antigen Laboratories
Post Your Comments:
(Date:11/27/2015)... ... 27, 2015 , ... MPWH, the No.1 Herpes-only dating community in the world, revealed that over ... More than 3.7 billion people under the age of 50 – or 67% of ... WHO's first global estimates of HSV-1 infection . , "The data shocks us highly!" ...
(Date:11/27/2015)... DE (PRWEB) , ... November 27, 2015 , ... ... member of the well-respected Microsoft Dynamics SL User Group (MSDSLUG). Recognized as Microsoft’s ... an independent group of Microsoft Dynamics SL software users, partners, industry experts and ...
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... ... failing. Secura Consultants has prided itself for not only fulfilling the needs of ... protection solutions at an affordable price and providing top-tier customer service. However, there's ...
(Date:11/27/2015)... ... ... CBD College is proud to announce that on November 20th, ... its Diagnostic Medical Sonography program. CBD College is honored to join this very short ... universities in the state of California make the cut. CBD College is officially the ...
(Date:11/27/2015)... ... ... Dr. Thomas Dunlap and Dr. Patrick Coleman , cardiologist ... Medicine at St., Joseph Health System’s Santa Rosa Memorial Hospital , co-hosted the ... ways and require time-critical intervention to avoid large area heart damage and progressive infections ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... Nov. 26, 2015 Research and Markets ... the "2016 Future Horizons and Growth Strategies ... Supplier Shares, Country Segment Forecasts, Competitive Intelligence, Emerging ... --> --> This ... the Italian therapeutic drug monitoring market, including emerging ...
(Date:11/25/2015)...  Amgen (NASDAQ: AMGN ) today announced the ... the United States (U.S.) Food and ... to Humira ® (adalimumab). Amgen believes this submission ... FDA and represents Amgen,s first BLA submission using the ... M.D., executive vice president of Research and Development at ...
(Date:11/25/2015)... Nov. 25, 2015  ARKRAY USA ... to provide evidence demonstrating the accuracy of its blood ... on Insulin Resistance, Diabetes and Cardiovascular Disease in ... the Company,s GLUCOCARD ® 01 meter and the ... requirements. The ability to accurately measure glucose levels in ...
Breaking Medicine Technology: